Resmed Inc. · NYSE:RMD
Resmed — Investor Presentation (September 2025)
16 slides from Resmed's investor presentation, September 2025
Slide 1: Resmed Stewardship Presentation
Resmed Stewardship Presentation September 2025 June 4, 2025
Slide 2: Presentation of financial information & forward-looking statements
Presentation of financial information & forward-looking statements Historical financial and operating data in this presentation reflect the consolidated results of ResMed Inc., its subsidiaries, and its legal entities for the periods indicated. This presentation includes financial information prepar
Slide 3: Fiscal 2025 highlights
Fiscal 2025 highlights Delivered Board of Employees are Compensation Focus on Committed to significant Directors is well- critical to the emphasizes pay sustainability aims engagement with stockholder value positioned to company’s for performance to both minimize stockholders, and in fiscal 2025 and
Slide 4: Resmed | The global leader in connected and digital health
Resmed | The global leader in connected and digital health Key Statistics1 Headquarters San Diego, CA 12% 12% Founded 1989 Revenue Revenue FY 2025 revenue $5.1B by business by region 36% 52% 30% 58% FY 2025 FY 2025 Listed (NYSE, ASX) 1995, RMD FY 2025 Operating Margin 33% | 34% (GAAP/Non-GAAP) Dev
Slide 5: Our goal is to empower 500 million lives in 2030
Our goal is to empower 500 million lives in 2030 We're proud to offer connected and digital heath tech solutions that people love, and that help those with sleep and breathing health challenges live happier, healthier lives with care in the comfort of the home or care setting of their choice During
Slide 6: Our 2030 Strategy
2030 OUR STRATEGY STRATEGY OUR OUR KEY FOCUS CAPABILITIES AREAS We will create products people love as well as Sleep Health seamless, personalized Empower our teams pathways for access to Breathing Health life-changing care Prioritize AI OUR OUR Health Tech at Home Build trust FINANCIAL MISSION GOAL
Slide 7: Board – overview
Board – overview Joined Board in past year. Christopher Jan De Witte, MSE, Karen Drexler, Michael J. Farrell, Peter C. Farrell, Carol J. Burt, BBA DelOrefice, BS, MBA BSE, MBA BE, SM, MBA PhD, DSc, AM MBA Independent Non-Executive Independent Non-Executive Independent Non-Executive Independent Non-E
Slide 8: Board – Committee structure
Board – Committee structure Committee Member Committee Chair Chairman of the Board Financial Expert Compensation and Leadership Compliance, Nominating and Board Members Audit Development Privacy and Quality Governance Carol J. Burt, BBA Christopher DelOrefice, BS, MBA Jan De Witte, MSE, MBA Karen Dr
Slide 9: Board – oversight of strategy
Board – oversight of strategy CASE STUDY: GLP-1s Assessing potential impacts of • Board actively participates in continued evolution of Resmed’s changing OSA landscape 2030 strategy Board briefing: ongoing monitoring of real- ‐ Executive leadership team regularly interacts with Board world evidence
Slide 10: Board – Key Committee responsibilities
Board – Key Committee responsibilities Board Audit Compensation and Leadership Compliance, Privacy Nominating and Governance Committee Development Committee and Quality Committee Committee Overseeing financial Overseeing compensation Overseeing compliance Evaluating each director’s independence, ris
Slide 11: Human capital management – overview
Human capital management – overview As of June 30, 2025, Resmed had ~10,600 employees • Resmed’s average global turnover 3,250 rate for fiscal year 2025 was 1,990 4,370 2,530 approximately 12% By By • Resmed encourages diversity of Function Geography 1,570 thought to ensure that both 4,240 employees
Slide 12: Human capital management – leadership team
Human capital management – leadership team Mick Farrell Brett Sandercock Mike Rider Vered Keisar Salli Schwartz Chief Executive Officer and Chairman of Chief Financial Officer Chief Legal Officer Chief People Officer Chief Investor Relations Officer the Board 19 years with Resmed 13 years with Resme
Slide 13: Executive compensation – program highlights
Executive compensation – program highlights Geographic Considerations Key Principles Resmed is headquartered in the US and the majority of our officers work and reside in To emphasize pay for performance the US. To be able to compete for best-in-industry talent in support of our growth and ensure al
Slide 14: Executive compensation – predominantly at-risk structure
Executive compensation – predominantly at-risk structure Base salary Cash incentive program Equity incentive program • Provides our • Rewards achievement of • Balanced, with 50% of grant value in long-term performance executives with a pre-established short-term units, and 50% in shorter term perfor
Slide 15: Sustainability practices – overview
Sustainability practices – overview • We aim to minimize Resmed’s environmental footprint across all operations and throughout our supply chain • We focus on designing and developing innovative products that have a lower environmental impact throughout their lifecycle • We are committed to conductin
Slide 16: Fiscal 2025 highlights
Fiscal 2025 highlights Delivered Board of Employees are Compensation Focus on Committed to significant Directors is well- critical to the emphasizes pay sustainability aims engagement with stockholder value positioned to company’s for performance to both minimize stockholders, and in fiscal 2025 and